On 23 March 2026, Cytiva announced that it has entered a contract with Yoshindo to support Yoshindo’s plans to establish biosimilar manufacturing capabilities for the Japanese market. Yoshindo expects to begin supplying biosimilars manufactured in its own plant in Toyama from 2028.
The contract between the companies relates to Cytiva’s FlexFactory™ solution, which “integrates standardised, modular bioprocessing technologies designed to shorten the time from facility design to GMP production without deep prior expertise in single-use systems”.
Yoshindo has previously partnered with Lupin in relation to an etanercept biosimilar in Japan and launched an ustekinumab biosimilar in Japan in May 2025 in collaboration with Biocon.